$ACHV
ACHIEVE LIFE SCIENCES, INC.

2020 Q4 Form 10-K Financial Statement

#000156459021012523 Filed on March 11, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.370M $1.860M $1.820M
YoY Change 63.45% -1.59% 11.66%
% of Gross Profit
Research & Development $2.347M $1.891M $1.103M
YoY Change 33.13% 3.67% -45.72%
% of Gross Profit
Depreciation & Amortization $70.00K $60.00K $70.00K
YoY Change 16.67% 0.0% 16.67%
% of Gross Profit
Operating Expenses $2.347M $1.891M $1.103M
YoY Change 33.13% 3.67% -45.72%
Operating Profit
YoY Change
Interest Expense $20.00K $0.00 $0.00
YoY Change -33.33% -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net -$3.000K -$10.00K -$4.000K
YoY Change -120.0% -122.73% -110.53%
Pretax Income -$4.720M -$3.760M -$2.920M
YoY Change 47.96% 2.45% -19.34%
Income Tax
% Of Pretax Income
Net Earnings -$4.724M -$3.764M -$2.922M
YoY Change 47.9% 2.48% -19.37%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.103M -$1.143M -$1.678M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.90M $22.40M $12.10M
YoY Change 114.97% 202.7% 16.35%
Cash & Equivalents $35.85M $22.44M $12.10M
Short-Term Investments
Other Short-Term Assets $1.100M $1.700M $500.0K
YoY Change 57.14% 466.67% 25.0%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $36.98M $24.10M $12.70M
YoY Change 113.31% 215.49% 17.57%
LONG-TERM ASSETS
Property, Plant & Equipment $42.00K $50.00K $300.0K
YoY Change -26.32% -21.88% 322.54%
Goodwill $1.034M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $187.0K $400.0K $500.0K
YoY Change 0.0% 110.53% 170.27%
Total Long-Term Assets $3.323M $3.500M $3.800M
YoY Change -11.24% -9.16% -3.87%
TOTAL ASSETS
Total Short-Term Assets $36.98M $24.10M $12.70M
Total Long-Term Assets $3.323M $3.500M $3.800M
Total Assets $40.30M $27.60M $16.50M
YoY Change 91.19% 140.17% 11.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $332.0K $300.0K $500.0K
YoY Change -61.35% -47.74% -29.28%
Accrued Expenses $2.600M $1.500M $1.300M
YoY Change 30.0% -42.31% -43.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.935M $1.800M $1.800M
YoY Change 2.3% -42.66% -39.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $100.0K $100.0K
YoY Change -50.0% -50.0% -66.67%
Total Long-Term Liabilities $100.0K $100.0K $100.0K
YoY Change -50.0% -50.0% -66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.935M $1.800M $1.800M
Total Long-Term Liabilities $100.0K $100.0K $100.0K
Total Liabilities $3.012M $1.900M $1.900M
YoY Change -0.53% -44.12% -41.56%
SHAREHOLDERS EQUITY
Retained Earnings -$60.43M
YoY Change 32.23%
Common Stock $97.72M
YoY Change 53.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.29M $25.68M $14.54M
YoY Change
Total Liabilities & Shareholders Equity $40.30M $27.60M $16.50M
YoY Change 91.19% 140.17% 11.83%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$4.724M -$3.764M -$2.922M
YoY Change 47.9% 2.48% -19.37%
Depreciation, Depletion And Amortization $70.00K $60.00K $70.00K
YoY Change 16.67% 0.0% 16.67%
Cash From Operating Activities -$2.480M -$4.330M -$2.200M
YoY Change -27.49% 41.04% -42.71%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K -$10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$10.00K -$10.00K
YoY Change -100.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.94M 14.62M 2.170M
YoY Change 25.41% -53.03%
NET CHANGE
Cash From Operating Activities -2.480M -4.330M -2.200M
Cash From Investing Activities 0.000 -10.00K -10.00K
Cash From Financing Activities 15.94M 14.62M 2.170M
Net Change In Cash 13.46M 10.28M -40.00K
YoY Change 44.89% -434.85% -101.28%
FREE CASH FLOW
Cash From Operating Activities -$2.480M -$4.330M -$2.200M
Capital Expenditures $0.00 -$10.00K -$10.00K
Free Cash Flow -$2.480M -$4.320M -$2.190M
YoY Change -27.49% 40.72% -42.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16664000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
670000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
17334000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
50000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
50000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
146000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
329000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
187000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
77000
CY2020Q4 us-gaap Liabilities
Liabilities
3012000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
76000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
97640000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60434000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
37286000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40298000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6111735
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6111735
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-14730000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
7879000
CY2018 achv Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1324000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
15802000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1201000
CY2019 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4000
CY2019 achv Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
4199000
CY2020 achv Shares Issued On Exercise Of Warrants Value
SharesIssuedOnExerciseOfWarrantsValue
3231000
CY2020 us-gaap Profit Loss
ProfitLoss
-14730000
CY2019 us-gaap Profit Loss
ProfitLoss
-16395000
CY2020 us-gaap Depreciation
Depreciation
32000
CY2019 us-gaap Depreciation
Depreciation
31000
CY2020 us-gaap Adjustment For Amortization
AdjustmentForAmortization
223000
CY2019 us-gaap Adjustment For Amortization
AdjustmentForAmortization
223000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1286000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1201000
CY2019 achv Cumulative Adjustments On Adoption Of Lease Standard
CumulativeAdjustmentsOnAdoptionOfLeaseStandard
3000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
452000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-194000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
341000
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-527000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10623000
CY2019 achv Increase Decrease In Accrued Clinical Liabilities
IncreaseDecreaseInAccruedClinicalLiabilities
-812000
CY2019 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
715000
CY2018 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-69000
CY2018 achv Increase Decrease In Accrued Clinical Liabilities
IncreaseDecreaseInAccruedClinicalLiabilities
322000
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
358000
CY2019 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-52000
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
710000
CY2020 achv Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
10000
CY2019 achv Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
-10000
CY2018 achv Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
4000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13474000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15216000
CY2020 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
280000
CY2019 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-328000
CY2018 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
310000
CY2020 achv Increase Decrease In Accrued Clinical Liabilities
IncreaseDecreaseInAccruedClinicalLiabilities
66000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3231000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4199000
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1324000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17325000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19757000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
53000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46000
CY2018 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
10000
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
25000
CY2018 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
5539000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5114000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
450000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5036000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5125000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19189000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7149000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4009000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16714000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9565000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5556000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35903000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and notes thereto. Actual results could differ from these estimates. Estimates and assumptions principally relate to estimates of the initial fair value and forfeiture rates of stock options issued to employees and consultants, the estimated compensation cost on performance restricted stock unit awards, clinical trial and manufacturing accruals, estimated useful lives of property, plant, equipment and intangible assets, estimates and assumptions in contingent liabilities. </p>
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020 achv Maturity Period Of Highly Liquid Investments To Be Considered As Cash Equivalent
MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent
P3M
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 achv Average Period To Maturity For Portfolio Of Cash And Marketable Securities
AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities
P0D
CY2015Q2 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
3100000
CY2015Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
223000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
223000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
223000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
223000
CY2020Q4 achv Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
972000
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2020Q4 us-gaap Cash
Cash
473000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2019Q4 us-gaap Cash
Cash
949000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
674000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
632000
CY2020 achv Period Of Not Utilizing Deferred Share Issuance Costs And Prepaid Amounts Related To Insurance
PeriodOfNotUtilizingDeferredShareIssuanceCostsAndPrepaidAmountsRelatedToInsurance
P12M
CY2020 achv Future Income Tax Rate Assumed For Deferred Tax Calculations
FutureIncomeTaxRateAssumedForDeferredTaxCalculations
0.21
CY2019 achv Future Income Tax Rate Assumed For Deferred Tax Calculations
FutureIncomeTaxRateAssumedForDeferredTaxCalculations
0.21
CY2018 achv Future Income Tax Rate Assumed For Deferred Tax Calculations
FutureIncomeTaxRateAssumedForDeferredTaxCalculations
0.21
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3490000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2664000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
116000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
70000
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-13000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-1416000
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-296000
CY2018 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-165000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Investment
IncomeTaxReconciliationTaxCreditsInvestment
23000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3662000
CY2018 achv Income Tax Reconciliation Book To Tax Return Adjustments
IncomeTaxReconciliationBookToTaxReturnAdjustments
20000
CY2019 achv Income Tax Reconciliation Unrecognized Tax Benefits
IncomeTaxReconciliationUnrecognizedTaxBenefits
7192000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3246000
CY2020 achv Income Tax Reconciliation Book To Tax Return Adjustments
IncomeTaxReconciliationBookToTaxReturnAdjustments
-518000
CY2019 achv Income Tax Reconciliation Book To Tax Return Adjustments
IncomeTaxReconciliationBookToTaxReturnAdjustments
-75000
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
25300000
CY2020 achv Unclaimed Tax Deductions Related To Scientific Research And Experimental Development Expenditures
UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures
16000000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
892000
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
891000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
35596000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33166000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7010000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
38000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
767000
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
800000
CY2019 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
-221000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-76000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-104000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-27000
CY2019 achv Income Tax Expense Benefit Excluding Adjustment For Reversal Of Deferred Tax Liability
IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability
-221000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
34800000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6256000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
466000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
315000
CY2020Q4 achv Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
3757000
CY2019Q4 achv Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
3501000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
164000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
79000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
183000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
181000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
48068000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
44389000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47539000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
43875000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
529000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
514000
CY2020Q4 achv Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
135000
CY2019Q4 achv Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
79000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
394000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
435000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
529000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
514000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
717000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
715000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
7000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2018 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
4000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
5000
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 achv Class Of Warrant Or Right Exercise Period
ClassOfWarrantOrRightExercisePeriod
P5Y
CY2018Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.00
CY2020 achv Class Of Warrant Or Right Cancellation Description
ClassOfWarrantOrRightCancellationDescription
Additionally, subject to certain exceptions, if, after the June 19, 2018, (i) the volume weighted average price of our common stock for each of 30 consecutive trading days, or the 2018 Measurement Period, which 2018 Measurement Period commences on June 19, 2018, exceeds 300% of the exercise price (subject to adjustments for stock splits, recapitalizations, stock dividends and similar transactions), (ii) the average daily trading volume for such 2018 Measurement Period exceeds $500,000 per trading day and (iii) certain other equity conditions are met, and subject to a beneficial ownership limitation, then we may call for cancellation of all or any portion of the warrants then outstanding.
CY2018Q2 achv Number Of Required Consecutive Days Weighted Average Trading Price For Cancelation Or Recall Of Warrants
NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants
P30D
CY2018Q2 achv Minimum Required Trading Price Percentage Over Exercise Price For Cancelation Or Recall Of Warrants
MinimumRequiredTradingPricePercentageOverExercisePriceForCancelationOrRecallOfWarrants
3.00
CY2018Q2 achv Minimum Required Trading Volume Value Per Day For Cancelation Or Recall Of Warrants
MinimumRequiredTradingVolumeValuePerDayForCancelationOrRecallOfWarrants
500000
CY2020 achv Gross Proceeds From Sale Of Warrants And Units
GrossProceedsFromSaleOfWarrantsAndUnits
13800000
CY2020 achv Warrant And Units Offering Cost Including Underwriting Discounts And Commissions
WarrantAndUnitsOfferingCostIncludingUnderwritingDiscountsAndCommissions
1600000
CY2020 achv Net Proceeds From Sale Of Warrants And Units
NetProceedsFromSaleOfWarrantsAndUnits
12200000
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2020 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
236
CY2019 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
256
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0094
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0252
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0878
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9425
CY2020 achv Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.00
CY2019 achv Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.00
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.76
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
50498
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
178380
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
30
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1406
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
227442
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
190.46
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.66
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
34874.40
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
227.61
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
44.64
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
227442
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
44.64
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P9Y1M17D
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
31814
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
221.96
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y7M24D
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2200000
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1800000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1000000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
900000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1000000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1500000
CY2020Q4 us-gaap Contractual Obligation
ContractualObligation
167000
CY2020Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
93000
CY2020Q4 us-gaap Contractual Obligation Due In Second And Third Year
ContractualObligationDueInSecondAndThirdYear
74000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
186000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
176000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
455000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M7D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M28D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0997
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0997
CY2020Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2020 achv Indemnification Expense
IndemnificationExpense
0
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1541000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1103000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1891000
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2347000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1816000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1815000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1863000
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2374000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
3357000
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
2918000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
3754000
CY2020Q4 us-gaap Costs And Expenses
CostsAndExpenses
4721000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
37000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10000
CY2020Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3320000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2922000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3764000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-4724000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.15
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.68
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.11
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4055000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2032000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1824000
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1763000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1885000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1630000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1893000
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1446000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
5940000
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
3662000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
3717000
CY2019Q4 us-gaap Costs And Expenses
CostsAndExpenses
3209000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
36000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
38000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
44000
CY2019Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5904000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-3624000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-3673000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-3194000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-17.57
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.08
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.07
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.91

Files In Submission

Name View Source Status
0001564590-21-012523-index-headers.html Edgar Link pending
0001564590-21-012523-index.html Edgar Link pending
0001564590-21-012523.txt Edgar Link pending
0001564590-21-012523-xbrl.zip Edgar Link pending
achv-10k_20201231.htm Edgar Link pending
achv-20201231.xml Edgar Link completed
achv-20201231.xsd Edgar Link pending
achv-20201231_cal.xml Edgar Link unprocessable
achv-20201231_def.xml Edgar Link unprocessable
achv-20201231_lab.xml Edgar Link unprocessable
achv-20201231_pre.xml Edgar Link unprocessable
achv-ex211_12.htm Edgar Link pending
achv-ex231_10.htm Edgar Link pending
achv-ex311_7.htm Edgar Link pending
achv-ex312_8.htm Edgar Link pending
achv-ex321_11.htm Edgar Link pending
achv-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending